CN114949250A - 用于递送治疗剂的组合物、药物组合物、制备方法以及用途 - Google Patents

用于递送治疗剂的组合物、药物组合物、制备方法以及用途 Download PDF

Info

Publication number
CN114949250A
CN114949250A CN202210547670.XA CN202210547670A CN114949250A CN 114949250 A CN114949250 A CN 114949250A CN 202210547670 A CN202210547670 A CN 202210547670A CN 114949250 A CN114949250 A CN 114949250A
Authority
CN
China
Prior art keywords
porous silicon
psinp
sirna
composition
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210547670.XA
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·J·赛勒
康珍英
朱珍明
埃米莉·安格林
埃斯特尔·科恩
马修·斯卡拉克
桑吉塔·巴蒂亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spinnaker Biosciences Inc
Massachusetts Institute of Technology
University of California San Diego UCSD
Original Assignee
Spinnaker Biosciences Inc
Massachusetts Institute of Technology
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spinnaker Biosciences Inc, Massachusetts Institute of Technology, University of California San Diego UCSD filed Critical Spinnaker Biosciences Inc
Publication of CN114949250A publication Critical patent/CN114949250A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Ceramic Engineering (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202210547670.XA 2016-04-14 2017-04-14 用于递送治疗剂的组合物、药物组合物、制备方法以及用途 Pending CN114949250A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662322782P 2016-04-14 2016-04-14
US62/322,782 2016-04-14
CN201780037192.5A CN109843301B (zh) 2016-04-14 2017-04-14 用于递送治疗剂的含金属硅酸盐的多孔硅材料
PCT/US2017/027772 WO2017181115A1 (en) 2016-04-14 2017-04-14 Porous silicon materials comprising a metal silicate for delivery of therapeutic agents

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780037192.5A Division CN109843301B (zh) 2016-04-14 2017-04-14 用于递送治疗剂的含金属硅酸盐的多孔硅材料

Publications (1)

Publication Number Publication Date
CN114949250A true CN114949250A (zh) 2022-08-30

Family

ID=60042009

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780037192.5A Active CN109843301B (zh) 2016-04-14 2017-04-14 用于递送治疗剂的含金属硅酸盐的多孔硅材料
CN202210547670.XA Pending CN114949250A (zh) 2016-04-14 2017-04-14 用于递送治疗剂的组合物、药物组合物、制备方法以及用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780037192.5A Active CN109843301B (zh) 2016-04-14 2017-04-14 用于递送治疗剂的含金属硅酸盐的多孔硅材料

Country Status (7)

Country Link
US (1) US20210177770A1 (enExample)
EP (1) EP3442540A4 (enExample)
JP (3) JP7093955B2 (enExample)
CN (2) CN109843301B (enExample)
AU (2) AU2017250300B2 (enExample)
CA (1) CA3021001A1 (enExample)
WO (1) WO2017181115A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116570721A (zh) * 2023-02-06 2023-08-11 四川农业大学 一种t-705@msn-rvg脑内药物递送载体及其制备方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210000744A1 (en) 2018-03-27 2021-01-07 The Regents Of The University Of California Drug delivery formulations
EA202092684A1 (ru) 2018-08-27 2021-03-11 Ридженерон Фармасьютикалз, Инк. Применение рамановской спектроскопии для последующей очистки
JP7335078B2 (ja) * 2019-02-21 2023-08-29 アサヒグループ食品株式会社 ペプチド含有物を含む組成物の変色抑制方法、並びに粉末組成物、顆粒、及び錠剤
WO2020171680A1 (ko) * 2019-02-22 2020-08-27 주식회사 레모넥스 면역활성 또는 암의 예방 또는 치료용 의약 조성물
GB201904336D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
GB201904334D0 (en) 2019-03-28 2019-05-15 Sisaf Ltd Carrier system for preparing herbaceous extracts
GB201904337D0 (en) * 2019-03-28 2019-05-15 Sisaf Ltd A delivery system
EP3714879A1 (en) 2019-03-28 2020-09-30 Sisaf Ltd Structured encapsulated silicon-containing particles
GB202110644D0 (en) * 2021-07-23 2021-09-08 Sisaf Ltd Improved nucleic acid vector particles
CN114983977B (zh) * 2022-06-30 2023-03-10 浙江大学 铜-聚多巴胺共修饰的多孔硅颗粒及其制备方法和应用
CN116510003B (zh) * 2023-06-20 2023-10-20 中国人民解放军军事科学院军事医学研究院 一种负载鼠疫菌rF1-V10蛋白的锰基纳米颗粒疫苗及其在抗鼠疫菌中的应用
WO2025098983A1 (en) * 2023-11-07 2025-05-15 Evonik Operations Gmbh Rna storage and delivery

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297441A1 (en) * 2005-09-22 2009-12-03 Leigh Trevor Canham Imaging Agents
CN103687590A (zh) * 2011-04-28 2014-03-26 Stc·Unm公司 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
CN103842769A (zh) * 2011-08-02 2014-06-04 加利福尼亚大学董事会 通过活细胞干涉测量法的快速、大量平行单细胞药物响应测量
CN104023711A (zh) * 2011-10-14 2014-09-03 Stc.Unm公司 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法
WO2014201276A1 (en) * 2013-06-12 2014-12-18 The Methodist Hospital Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents
WO2015095608A1 (en) * 2013-12-20 2015-06-25 Colgate-Palmolive Company Core shell silica particles and use for malodor reduction

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434260A (en) 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
JPH07216256A (ja) * 1994-01-28 1995-08-15 Suzuki Yushi Kogyo Kk 着色微粒子とその製造方法
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
GB0118689D0 (en) * 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
JP2005503395A (ja) 2001-08-22 2005-02-03 ワイス ラパマイシンジアルデヒド
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
AU2003208935A1 (en) 2002-02-07 2003-09-02 The Regents Of The University Of California Optically encoded particles
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7563451B2 (en) * 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
US8308066B2 (en) 2003-12-22 2012-11-13 The Regents Of The University Of California Method for forming optically encoded thin films and particles with grey scale spectra
AU2004308380A1 (en) 2003-12-22 2005-07-14 The Regents Of The University Of California Optically encoded particles, system and high-throughput screening
US20090208556A1 (en) 2004-10-29 2009-08-20 Regents Of The University Of California, The Porous photonic crystals for drug delivery to the eye
US20140336514A1 (en) * 2005-08-05 2014-11-13 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
US8916198B2 (en) 2006-04-25 2014-12-23 Washington State University Mesoporous calcium silicate compositions and methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents
NZ583120A (en) 2007-07-10 2012-03-30 Univ California Materials and methods for delivering compositions to selected tissues
EP2427179A4 (en) * 2009-05-04 2013-09-11 Psivida Inc POROUS SILICON MEDICATION ELUTING PARTICLES
US9421173B2 (en) * 2011-09-21 2016-08-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Nano delivery systems for siRNA
CN102552972A (zh) * 2011-12-22 2012-07-11 南京工业大学 金属离子修饰介孔氧化硅及其制备方法
WO2014130998A1 (en) 2013-02-25 2014-08-28 Spinnaker Biosciences, Inc. Surface functionalized porous silicon
US11400032B2 (en) * 2013-12-20 2022-08-02 Colgate-Palmolive Company Tooth whitening oral care product with core shell silica particles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090297441A1 (en) * 2005-09-22 2009-12-03 Leigh Trevor Canham Imaging Agents
CN103687590A (zh) * 2011-04-28 2014-03-26 Stc·Unm公司 用于靶向给药的多孔纳米颗粒支撑脂双层（原始细胞）及其使用方法
CN103842769A (zh) * 2011-08-02 2014-06-04 加利福尼亚大学董事会 通过活细胞干涉测量法的快速、大量平行单细胞药物响应测量
CN104023711A (zh) * 2011-10-14 2014-09-03 Stc.Unm公司 用于靶向递送(包括负载物的透皮递送)的多孔纳米颗粒支撑的脂质双层(原始细胞)及其方法
WO2014201276A1 (en) * 2013-06-12 2014-12-18 The Methodist Hospital Polycation-functionalized nanoporous silicon carrier for systemic delivery of gene silencing agents
WO2015095608A1 (en) * 2013-12-20 2015-06-25 Colgate-Palmolive Company Core shell silica particles and use for malodor reduction

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116570721A (zh) * 2023-02-06 2023-08-11 四川农业大学 一种t-705@msn-rvg脑内药物递送载体及其制备方法

Also Published As

Publication number Publication date
JP7093955B2 (ja) 2022-07-01
AU2017250300A1 (en) 2018-11-01
AU2023204322B2 (en) 2025-08-21
EP3442540A4 (en) 2019-12-18
US20210177770A1 (en) 2021-06-17
JP2019511582A (ja) 2019-04-25
AU2023204322A1 (en) 2023-07-27
JP2022121463A (ja) 2022-08-19
WO2017181115A1 (en) 2017-10-19
AU2017250300B2 (en) 2023-04-06
CA3021001A1 (en) 2017-10-19
CN109843301A (zh) 2019-06-04
JP2024094359A (ja) 2024-07-09
EP3442540A1 (en) 2019-02-20
CN109843301B (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
AU2023204322B2 (en) Porous silicon materials comprising a metal silicate for delivery of therapeutic agents
Yan et al. Layered double hydroxide nanostructures and nanocomposites for biomedical applications
Hu et al. Layered double hydroxide-based nanomaterials for biomedical applications
Khatoon et al. Nanoclay-based drug delivery systems and their therapeutic potentials
Kang et al. Self-sealing porous silicon-calcium silicate core-shell nanoparticles for targeted siRNA delivery to the injured brain
Joo et al. Porous silicon–graphene oxide core–shell nanoparticles for targeted delivery of siRNA to the injured brain
Du et al. Disulfide‐bridged organosilica frameworks: designed, synthesis, redox‐triggered biodegradation, and nanobiomedical applications
Park et al. Photoluminescent and biodegradable porous silicon nanoparticles for biomedical imaging
Perez et al. Silica-based multifunctional nanodelivery systems toward regenerative medicine
Kang et al. Optical imaging and anticancer chemotherapy through carbon dot created hollow mesoporous silica nanoparticles
Sokolova et al. Inorganic nanoparticles as carriers of nucleic acids into cells
JP2021130708A (ja) 融合性リポソーム被覆多孔質ケイ素ナノ粒子
Zou et al. Programmed packaging of mesoporous silica nanocarriers for matrix metalloprotease 2-triggered tumor targeting and release
Meshkini et al. Methotrexate-F127 conjugated mesoporous zinc hydroxyapatite as an efficient drug delivery system for overcoming chemotherapy resistance in osteosarcoma cells
CN111787912A (zh) 用于核酸分子递送的纳米颗粒-水凝胶复合物
EP3154521B1 (en) Disintegratable core/shell silica particles for encapsulating and releasing bioactive macromolecules
Hou et al. A novel high drug loading mussel-inspired polydopamine hybrid nanoparticle as a pH-sensitive vehicle for drug delivery
Liu et al. Porous nanomaterials for biosensing and related biological application in in vitro/vivo usability
US10905653B2 (en) Sequentially decomposable polypeptide-based nanocarriers with protective shell and preparation thereof
US11618901B2 (en) Anti-miRNA carrier conjugated with a peptide binding to a cancer cell surface protein and use thereof
Avitabile et al. Recent Cutting‐Edge Technologies for the Delivery of Peptide Nucleic Acid
KR102050043B1 (ko) 메조기공 실리카 입자 및 상기 입자의 표면 및 기공 내에 siRNA와 결합 가능한 금속이온을 포함하는 siRNA 전달체, 이의 제조방법 및 용도
KR102012469B1 (ko) siRNA 및 메조기공 실리카 나노입자가 금속 이온으로 결합된 siRNA 전달체, 이의 제조방법 및 용도
Fattahi et al. Nanodiamonds as next generation carriers in exploring therapeutic benefits
ES2367959B1 (es) Particulas magnético-luminiscentes para aplicaciones biomédicas.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220830

WD01 Invention patent application deemed withdrawn after publication